United Therapeutics reported $3.48B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Amarin USD 602.76M 23.26M Jun/2026
Ardelyx USD 381.87M 447K Mar/2026
Baxter International USD 6.99B 142M Jun/2026
Bayer EUR 35.3B 2.39B Mar/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Insmed USD 1.63B 20.75M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
J&J USD 59.77B 601M Jun/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Moderna USD 5.82B 45M Jun/2026
Omeros USD 69.65M 26.53M Jun/2025
Pfizer USD 41.36B 1.46B Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Teva Pharmaceutical Industries USD 13.76B 50M Jun/2026
United Therapeutics USD 3.48B 611.7M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026